7-(2-fluorobenzyl)-4-(2-furyl)-7H-pyrrolo[2,3-d]pyrimidine-2-amine | 442847-51-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: 7-(2-fluorobenzyl)-4-(2-furyl)-7H-pyrrolo[2,3-d]pyrimidine-2-amine
• 英文别名: 7-[(2-fluorophenyl)methyl]-4-(furan-2-yl)pyrrolo[2,3-d]pyrimidin-2-amine
• CAS: 442847-51-0
• 化学式: C₁₇H₁₃FN₄O
• 分子量: 308.315
• InChiKey: HFFBFYRTHLQYHB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  69.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-(3,4-dimethoxybenzyl)-7-(2-fluorobenzyl)4-(2-furyl)-7H-pyrrolo[2,3-d]pyrimidine-2-amine 在 三氟乙酸 作用下， 以51%的产率得到7-(2-fluorobenzyl)-4-(2-furyl)-7H-pyrrolo[2,3-d]pyrimidine-2-amine
  参考文献：
  名称：

  人腺苷A2A受体的拮抗剂。第3部分：吡唑并[3,4-d]嘧啶，吡咯并[2,3-d]嘧啶和6-芳基嘌呤的设计与合成。

  摘要：

  描述了一系列的吡唑并[3,4-d]嘧啶，吡咯并[2,3-d]嘧啶和6-芳基嘌呤腺苷A（2A）拮抗剂。许多示例对人类A（1）受体亚型具有高度选择性，并且在帕金森氏病的体内模型中具有活性。

  DOI：

  10.1016/j.bmcl.2008.03.072

文献信息

• Pyrrolo[2,3-d]pyrimidine and their use as purinergic receptor antagonists
  申请人：——

  公开号：US20040092537A1

  公开（公告）日：2004-05-13

  Use of a compound of the formula (I) wherein R 1 is selected from alkyl, alkoxy, aryloxy, alkylthio, arylthio, aryl, halogen, CN, NR 7 R 8 , NR 6 COR 7 , NR 6 CO 2 R 9 and NR 6 SO 2 R 9 ; R 2 is selected from aryl attached via an unsaturated carbon; R 3 and R 4 are independently selected from H, alkyl, halogen, alkoxy, alkylthio, CN and NR 7 R 8 ; R 5 is selected from H, acyclic alkyl, COR 6 , CONR 7 R 8 , CONR 6 NR 7 R 8 , CO 2 R 9 and SO 2 R 9 ; R 6 , R 7 and R 8 are independently selected from H, alkyl and aryl or where R 7 and R 8 are in an NR 7 R 8 group R 7 and R 8 may be linked to form a hererocyclic group, or where R 6 , R 7 and R 8 are in a (CONR 6 NR 7 R 8 ) group, R 6 and R 7 may be linked to form a hererocyclic group; and R 9 is selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A 2A receptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or for neuroprotection in a subject; compounds of formula (I) for use in therapy; and novel compounds of formula (I) per se. 1

  使用公式（I）的化合物，其中R1选择自烷基，烷氧基，芳氧基，烷硫基，芳硫基，芳基，卤素，CN，NR7R8，NR6COR7，NR6CO2R9和NR6SO2R9; R2选择通过不饱和碳连接的芳基; R3和R4分别选择自H，烷基，卤素，烷氧基，烷硫基，CN和NR7R8; R5选择自H，非环状烷基，COR6，CONR7R8，CONR6NR7R8，CO2R9和SO2R9; R6，R7和R8分别选择自H，烷基和芳基，或者当R7和R8在NR7R8组中时，R7和R8可以连接形成杂环基团，或者当R6，R7和R8在（CONR6NR7R8）组中时，R6和R7可以连接形成杂环基团; R9选择自烷基和芳基，或其药学上可接受的盐或前药，在制备治疗或预防阻断嘌呤受体，特别是腺苷受体，尤其是A2A受体可能有益的紊乱的药物中使用，特别是其中所述紊乱是运动障碍，如帕金森病，或所述紊乱是抑郁症，认知或记忆障碍，急性或慢性疼痛，注意力缺陷多动障碍或嗜睡症，或用于保护神经元。公式（I）的化合物用于治疗; 和公式（I）的新化合物本身。
• Pyrrolo [2,3-d] pyrimidine and their use as purinergic receptor antagonists
  申请人：Gillespie John Roger

  公开号：US20060128731A1

  公开（公告）日：2006-06-15

  Use of a compound of the formula (I) wherein R 1 is selected from alkyl, alkoxy, aryloxy, alkylthio, arylthio, aryl, halogen, CN, NR 7 R 8 , NR 6 COR 7 , NR 6 CO 2 R 9 and NR 6 SO 2 R 9 ; R 2 is selected from aryl attached via an unsaturated carbon; R 3 and R 4 are independently selected from H, alkyl, halogen, alkoxy, alkylthio, CN and NR 7 R 8 ; R 5 is selected from H, acyclic alkyl, COR 6 , CONR 7 R 8 , CONR 6 NR 7 R 8 , CO 2 R 9 and SO 2 R 9 ; R 6 , R 7 and R 8 are independently selected from H, alkyl and aryl or where R 7 and R 8 are in an NR 7 R 8 group R 7 and R 8 may be linked to form a hererocyclic group, or where R 6 , R 7 and R s are in a (CONR 6 NR 7 R s ) group, R 6 and R 7 may be linked to form a hererocyclic group; and R 9 is selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A 2A receptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or for neuroprotection in a subect; compounds of formula (I) for use in therapy; and novel compounds of formula (I) per se.

  使用式(I)的化合物，其中R1选择自烷基，烷氧基，芳氧基，烷硫基，芳硫基，芳基，卤素，CN，NR7R8，NR6COR7，NR6CO2R9和NR6SO2R9; R2选择通过不饱和碳连接的芳基; R3和R4分别选择自H，烷基，卤素，烷氧基，烷硫基，CN和NR7R8; R5选择自H，非环状烷基，COR6，CONR7R8，CONR6NR7R8，CO2R9和SO2R9; R6，R7和R8分别选择自H，烷基和芳基，或者R7和R8在NR7R8基团中，R7和R8可以连接形成杂环基团，或者R6，R7和Rs在(CONR6NR7Rs)基团中，R6和R7可以连接形成杂环基团; R9选择自烷基和芳基，或其药学上可接受的盐或前药，在制备治疗或预防阻断嘌呤受体，特别是腺苷受体，尤其是A2A受体可能有益的紊乱的药物中使用，特别是其中所述紊乱是运动障碍，如帕金森病，或所述紊乱是抑郁症，认知或记忆障碍，急性或慢性疼痛，ADHD或嗜睡症，或用于主体的神经保护; 公式(I)的化合物用于治疗; 以及公式(I)的新化合物本身。
• PYRROLO 2,3-d]PYRIMIDINE AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS
  申请人：VERNALIS RESEARCH LIMITED

  公开号：EP1363639A1

  公开（公告）日：2003-11-26
• PYRROLO 2,3-d PYRIMIDINE AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS
  申请人：VERNALIS RESEARCH LIMITED

  公开号：EP1363639B1

  公开（公告）日：2008-08-20
• US7098333B2
  申请人：——

  公开号：US7098333B2

  公开（公告）日：2006-08-29